Skip to main content
Premium Trial:

Request an Annual Quote

No More Stuffy Noses or Hacking Coughs

Could a universal flu vaccine be in the works? 

Two teams of researchers recently separately reported progress in developing vaccines that could offer protection against multiple flu strains by targeting the stem hemagglutinin glycoprotein of the flu virus, offering a new approach to confer immunity. 

In research published in Science, scientists from the US and the Netherlands demonstrated the use of their approach on monkeys, while another group of researchers from the US and Japan published the results of their work conducted on mice and ferrets in Nature Medicine

The key to both teams' research is that they targeted the stems that connect the ends of the hemagglutinin to the rest of the flu virus. Typically, flu vaccines work by causing the human immune system to produce antibodies to attach to the flu virus's hemagglutinin, used by the virus to access a person's cells. The antibodies prevent the virus from accessing the cells, but in each flu strain the hemagglutinin is structured differently. Adding to the virus's slippery nature is that it changes genetically rapidly, rendering one season's vaccine useless the next season. 

Because the hemagglutinin's stems are structurally similar from strain to strain, an antibody attacking the stem should be able to protect against multiple strains, the theory goes. 

While the new vaccine type is still years away from having any clinical use, the two studies are seen as breakthroughs by some. Peter Palese, a flu expert at Mount Sinai Hospital told The Huffington Post that the studies are "very good…There are no problems with them. What we need to do now is put [the vaccines] in humans and see if they work." 

But even if they do, it is unknown how long they would confer immunity, since no one knows for how long the vaccines would trigger the body to produce sufficient amounts of the antibodies that target the stems.   

"The goal would be to try to make it so that you don't have to get immunized every year — but maybe once every five or 10 years," Scripps Research Institute researcher and an author of the Science paper Ian Wilson told The Huffington Post. "That would be a major step forward."

Filed under

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.